PolyBio

From Crisis to Cure: PolyBio is supporting top HIV researchers to pivot into the study and treatment of Long COVID. Watch the full video to learn how this collaboration is being maximized & driving forward innovative research: youtu.be/6kC1lyY6hPc?si…

The PolyBio-supported Lumbrokinase trial for Long COVID, ME/CFS, and Post-Treatment Lyme is now open for remote participation to patients across the US. Email the clinical team to register now at CoreResearch@MountSinai.org.

Excited to announce the decentralization of our lumbrokinase trial @polybioRF, now open it to patients with #LongCOVID, #MECFS, and #chronicLyme throughout the cont. US. You will receive the drug by mail & complete VIRTUAL study visits. Enroll at CoREresearch@mountsinai.org!

We’re proud to have Dr. Steve Deeks, who has garnered decades of experience researching HIV diagnostics & treatments, leading PolyBio’s VIPER diagnostics program for Long Covid. Said Dr. Deeks, “Having witnessed how a single test can transform a complex disease like HIV, I am fully committed to doing my part to develop tests for Long COVID. Validated diagnostics will allow us to run smarter, more targeted trials - and ultimately deliver effective treatments to patients faster.”

PolyBio Long Covid diagnostics program donor Steve Pagliuca is going for the 3-pointer with his recent efforts to support our research. Check out Steve’s March Madness bracket in Bloomberg’s “Brackets for a Cause.” In the top 20 right now is Pagliuca—let’s hope he brings home the win for PolyBio’s LCCI program. bloomberg.com/graphics/2026-…

Steve Pagliuca, former co-chairman of Bain Capital & Founder of PagsGroup, is part of a donor coalition supporting the VIPER diagnostics program for Long COVID. "Long COVID represents one of the most urgent unmet medical challenges of our time,” said Pagliuca. “Scientific insights are advancing, but they are not yet reaching patients. The Long COVID Cure Initiative is changing that by systematically accelerating the path from discovery to real-world treatments." VIPER is the first step in the broader LLCI program, which will act as a pipeline to bring diagnostics & treatments directly to patients.

@ishbelfrazer @microbeminded2 We funded this $1M ME/CFS project with the same team at UCSF running VIPER. Findings will be fed into our same pipeline to innovate diagnostics for ME/CFS: polybio.org/projects/expan…

@microbeminded2 @polybioRF I still remember years ago you when promised to help pwME. You gave me so much hope which has now long gone.

I’m so excited for the VIPER program to launch as part of our @polybioRF Long COVID Cure Initiative program! VIPER will validate the top diagnostic tests for SARS-CoV-2 persistence and other biological drivers of Long COVID - providing a path to more targeted treatments

13/ VIPER is the first phase of the Long COVID Cure Initiative (LCCI), a four-step program created by PolyBio to translate biological insights into real-world impact. By linking validated diagnostics to clinical trials and therapeutic development, LCCI is designed to move beyond discovery and deliver scalable, patient-ready solutions for millions affected by Long COVID.

12/ “The VIPER program builds the diagnostic foundation required to translate discovery into care, enabling smarter clinical trials and a coordinated path to treatments that actually match the biology of the disease,” said healthcare philanthropist Greg White. “This is the kind of rigorous, integrated infrastructure needed to move an entire Long COVID field forward.

Breaking: PolyBio Research Foundation today announced the launch of VIPER, the first large-scale program designed to rigorously validate diagnostic tests that measure SARS-CoV-2 persistence and other biological drivers of Long COVID: prnewswire.com/news-releases/…

2/ @TickBootCamp Watch the full interview here: youtu.be/kcRi_lUudPo?si…

Dr. Amy Proal on the Tick Bootcamp podcast last week: “If you’re a pathogen and you’re going to infect someone, and persist in their body, the blood is not a smart place to be... A lot of pathogens over time will hide in a person’s tissue… Where they’re somewhat able to evade immune recognition.”